Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NAVB NASDAQ:NLTX NYSE:VNRX NASDAQ:VRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNAVBNavidea Biopharmaceuticals$0.00$0.00$0.00▼$0.13$50K1.997,316 shs10,188 shsNLTXNeoleukin Therapeutics$19.00-5.4%$20.74$2.03▼$14.36$178.56M1.1150,104 shs123,069 shsVNRXVolitionRx$0.66+4.5%$0.67$0.40▼$0.94$70.59M1.27198,505 shs273,752 shsVRMLVermillion$0.450.0%$3.26$0.35▼$5.78$43.80M3.47440,144 shs39,008 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNAVBNavidea Biopharmaceuticals0.00%0.00%0.00%-28.57%-50.00%NLTXNeoleukin Therapeutics+7.96%+2.40%+4.47%+1.62%-48.96%VNRXVolitionRx+4.54%+8.99%+5.82%+3.19%-6.14%VRMLVermillion-1.12%-1.40%+102.48%+221.36%-50.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNAVBNavidea Biopharmaceuticals$0.00$0.00$0.00▼$0.13$50K1.997,316 shs10,188 shsNLTXNeoleukin Therapeutics$19.00-5.4%$20.74$2.03▼$14.36$178.56M1.1150,104 shs123,069 shsVNRXVolitionRx$0.66+4.5%$0.67$0.40▼$0.94$70.59M1.27198,505 shs273,752 shsVRMLVermillion$0.450.0%$3.26$0.35▼$5.78$43.80M3.47440,144 shs39,008 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNAVBNavidea Biopharmaceuticals0.00%0.00%0.00%-28.57%-50.00%NLTXNeoleukin Therapeutics+7.96%+2.40%+4.47%+1.62%-48.96%VNRXVolitionRx+4.54%+8.99%+5.82%+3.19%-6.14%VRMLVermillion-1.12%-1.40%+102.48%+221.36%-50.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNAVBNavidea Biopharmaceuticals 0.00N/AN/AN/ANLTXNeoleukin Therapeutics 0.00N/AN/AN/AVNRXVolitionRx 3.00Buy$3.50433.46% UpsideVRMLVermillion 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VRML, VNRX, NAVB, and NLTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/15/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/17/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.007/9/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNAVBNavidea Biopharmaceuticals$8.13K6.16N/AN/AN/A∞NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/AVNRXVolitionRx$1.32M53.51N/AN/A($0.11) per share-5.96VRMLVermillion$4.54M9.65N/AN/A$0.09 per share5.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/ANLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/AVNRXVolitionRx-$35.32M-$0.25N/A∞N/A-2,321.14%N/A-163.39%N/AVRMLVermillion-$15.24MN/AN/A∞N/A-307.31%-155.25%-103.47%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/AVRMLVermillionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNAVBNavidea BiopharmaceuticalsN/AN/AN/ANLTXNeoleukin TherapeuticsN/A15.3315.33VNRXVolitionRxN/A0.220.22VRMLVermillion0.202.512.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNAVBNavidea Biopharmaceuticals0.01%NLTXNeoleukin Therapeutics52.37%VNRXVolitionRx8.09%VRMLVermillion18.09%Insider OwnershipCompanyInsider OwnershipNAVBNavidea Biopharmaceuticals43.68%NLTXNeoleukin Therapeutics1.58%VNRXVolitionRx10.40%VRMLVermillion4.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataVNRXVolitionRx80107.60 million80.80 millionOptionableVRMLVermillion4397.38 millionN/ANot OptionableVRML, VNRX, NAVB, and NLTX HeadlinesRecent News About These CompaniesVermillion authorities investigate car vs building crashAugust 10, 2024 | keloland.comKVermillion, SD Hourly Weather ForecastApril 30, 2024 | wunderground.comWVermillion named Tree City USAApril 21, 2024 | siouxcityjournal.comSVermillion girls' basketball rallies to win Class A state titleMarch 13, 2024 | siouxcityjournal.comSPeoria police thwart school shooting; teen could be charged as an adultFebruary 18, 2024 | pjstar.comP2023 HW Vanguard: Dale VermillionOctober 15, 2023 | housingwire.comHGoodwill coming to VermillionSeptember 17, 2023 | siouxcityjournal.comSIn Telangana, Vermillion And Saffron Threads Were Used To Lure Women VotersSeptember 2, 2023 | outlookindia.comVermillion, SD 10-Day Weather ForecastJuly 17, 2023 | wunderground.comWA cold case without a crime: Inside the messy investigation into two missing SD teens in 1971June 21, 2023 | grandforksherald.comGCamellia VermillionJune 16, 2023 | health.usnews.comDr. Richard L. KnutsonJune 6, 2023 | health.usnews.comVermillion Elementary SchoolMay 24, 2023 | usnews.comDr. Kenneth J. VermillionMay 20, 2023 | health.usnews.comGolf: Vermillion Runner-Up At Huskies Invitational | Sports | plaintalk ... - Vermillion Plain TalkMay 13, 2023 | news.google.comNDriver killed after veering into path of dump truck on Highway 52 - Bring Me The NewsMay 13, 2023 | news.google.comNFatal crash in Vermillion Township closes portion of Highway 52 - CBS NewsMay 13, 2023 | news.google.comNVermillion, KS Weather ConditionsMay 13, 2023 | wunderground.comWVermillion Softball Falls To Tea Area 12-2 | Sports | plaintalk.net - Vermillion Plain TalkMay 13, 2023 | news.google.comNBaseball: Dakota Valley Blanks Vermillion 7-0 | Sports | plaintalk.net - Vermillion Plain TalkMay 13, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVRML, VNRX, NAVB, and NLTX Company DescriptionsNavidea Biopharmaceuticals NYSE:NAVB$0.0005 0.00 (0.00%) As of 09/12/2025 03:53 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Neoleukin Therapeutics NASDAQ:NLTX$19.00 -1.08 (-5.38%) As of 09/12/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.VolitionRx NYSE:VNRX$0.66 +0.03 (+4.54%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$0.66 0.00 (-0.02%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.Vermillion NASDAQ:VRMLVermillion, Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women. It also offers in-vitro diagnostic (IVD) trial services to third-party customers; and laboratory services to meet the needs of IVD manufacturers to commercialize high-complexity assays. The company serves clinical reference laboratories, hospital laboratories, and physician offices. Vermillion, Inc. was founded in 1993 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
